Hypercell& Abfinder AI: Fast, Highthroughput/Fidelity Antibody Discovery Platform

Please register via: https://us06web.zoom.us/webinar/register/WN_tsbosQNFR0SoynpSNkUDfw

Abstract:

The path from antibody discovery to clinical manufacturing is often bottlenecked by downstream developability failures. Traditional screening pipelines prioritize antigen affinity while ignoring critical biophysical risks, leading to costly late-stage attrition. This webinar introduces a unified, fast-tracked workflow that bridges the gap between physical single-cell discovery and predictive computer-aided engineering by combining the HyperCell® platform and AbFinder AI™.

The HyperCell® microfluidic system accelerates upstream workflows by screening hundreds of thousands of single antibody-secreting cells in a single day, preserving cell viability while ensuring high-throughput recovery. Sequences isolated from this high-diversity pool are directly processed by the AbFinder AI™ developability module. This computational core evaluates key structural parameters, including antibody aggregation, instability index, CDR loop length, and positive self-association (PSH).

Crucially, these predictive features serve as accurate suroragtes for thermal and colloidal stability, allowing researchers to flag structural weaknesses and low melting temperatures (\(T_{m}\)) prior to physical expression. Attendees will learn how this integrated "wet-lab speed meets dry-lab intelligence" approach transforms antibody discovery. It empowers researchers to screen and filter candidates concurrently, selecting leads optimized for both target affinity and manufacturing success.

Speaker Bio:

Na An is a dynamic life sciences professional with a unique blend of deep scientific expertise and commercial strategy, currently serving as a Product Manager at Bioelectronica Holdings, Inc. In her role at Bioelectronica, she drives the lifecycle and deployment of cutting-edge technologies that fuse digital biochemistry, computer vision, and AI to transform the antibody discovery pipeline.